Experiences of misuse and symptoms of dependence among people who use gabapentinoids: a qualitative systematic review protocol

Author:

McNeilage Amy GrayORCID,Nielsen SuzanneORCID,Murnion Bridin,Ashton-James ClaireORCID

Abstract

IntroductionGabapentinoids are among the most widely prescribed pain medications. However, there is growing evidence to suggest that gabapentinoids may be associated with dependence and misuse. The aim of this systematic review is to synthesise the qualitative literature on gabapentinoid misuse and symptoms of dependence. The findings of this study will inform efforts to mitigate emerging harms.Methods and analysisA systematic review of qualitative research will explore lived experiences of misuse and symptoms of dependence among people who use gabapentinoids. Six databases (MEDLINE, Scopus, Web of Science, CINAHL, EMBASE and PsycINFO) and grey literature sources will be searched from inception to May 2023. Qualitative studies that include people with lived experiences of gabapentinoid misuse and symptoms of gabapentinoid dependence will be included. Reference lists of included studies will also be screened for additional studies. The methodological quality of included studies will be appraised using the Critical Appraisal Skills Programme qualitative checklist, and higher quality studies will be prioritised in the thematic synthesis. The GRADE-CERQual approach will be used to assess confidence in the overall findings of the review.Ethics and disseminationEthical approval is not required for this systematic review. The findings of this review will be disseminated in peer-reviewed journals, at conferences and on social media.PROSPERO registration numberCRD42023401832.

Funder

Pain Foundation

Australian Government

Publisher

BMJ

Subject

General Medicine

Reference34 articles.

1. Gabapentinoid use in the United States 2002 through 2015;Johansen;JAMA Intern Med,2018

2. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017

3. Pharmaceutical Benefits . PBSExpenditure and prescriptions report 1 July 2021 to 30 June 2022:department of health, . 2022 Available: https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions

4. Pharmaceutical Benefits Scheme . expenditure and prescriptions twelve months to 30 June 2013. department of health. 2013. Available: https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions

5. Alpha2Delta ligands, Gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use;Calandre;Expert Rev Neurother,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3